ALDEI.PA Deinove SA EURONEXT €0.03 16 Jan 2026: volume spike guides intraday outlook
The ALDEI.PA stock is trading at €0.03 on EURONEXT in Europe on 16 Jan 2026, led by a surge in intraday volume of 13,014,939 shares. Traders are reacting to biotech pipeline updates and the stock’s extreme microcap profile. Volume is more than twice the average, which has amplified intraday volatility. We track price action, key ratios, Meyka AI grade and a model forecast to frame near-term opportunities and risks for Deinove SA.
Intraday price and volume snapshot for ALDEI.PA stock
Deinove SA (ALDEI.PA) opened at €0.02 and trades between a day low of €0.02 and a day high of €0.03 on EURONEXT. Current reported volume is 13,014,939, versus an average volume of 5,992,347, giving a relative volume of 2.17. Market cap stands at €1,134,989, reflecting a microcap structure that magnifies news-driven moves.
What is driving ALDEI.PA stock intraday
Intraday flows reflect speculative buying tied to Deinove’s biotechnology assets, notably antibiotic candidate DNV3837 in Phase II and cosmetic ingredients licensing. The Healthcare sector is mixed, and small-cap biotech names often out- or under-perform sector averages. With limited public news today, higher-than-normal volume suggests short-term trader interest rather than broad institutional repositioning.
Meyka stock grade and technical signals for ALDEI.PA stock
Meyka AI rates ALDEI.PA with a score out of 100: 61.07, Grade B, Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus. On technicals, the price sits above the 50-day average (€0.02) but below the 200-day average (€0.11), indicating short-term momentum inside a longer-term downtrend.
Valuation and financial snapshot for ALDEI.PA stock
Deinove reports negative earnings per share (EPS -0.24) and a negative PE ratio, reflecting ongoing losses. Key ratios: price-to-sales 3.09, cash per share €0.13, and current ratio 1.36. Enterprise value is about €3,613,989, showing leverage relative to the tiny market cap and limited free cash flow. These metrics underline a high-risk valuation profile for investors.
Analyst coverage, price targets and ALDEI.PA stock forecast
Analyst coverage is sparse for ALDEI.PA stock; no consensus price target is published. Meyka AI’s forecast model projects €0.05 in 12 months. Compared with the reference price €0.0265, that implies an upside of +88.68%, though model outputs are projections and not guarantees. We provide conservative and optimistic price bands to frame scenarios for traders.
Trading risks and opportunities for ALDEI.PA stock
Opportunities: clinical-readout catalysts and licensing deals could re-rate the stock quickly because of the small float. Risks: extreme volatility, limited liquidity, potential dilution and negative operating margins. Year high and low are €0.44 and €0.01 respectively, showing the stock’s wide trading range and episodic investor interest in the biotech sector.
Final Thoughts
Key takeaways for the ALDEI.PA stock on 16 Jan 2026: intraday activity shows a clear volume surge to 13,014,939 shares, pushing the price to €0.03 while microcap structure magnifies moves. Meyka AI rates ALDEI.PA at 61.07/100 (Grade B, HOLD) based on benchmark and company metrics. Our forecast model projects €0.05 in 12 months, versus the reference price €0.0265, implying an upside of +88.68%. That forecast assumes successful pipeline progress or partnership news; failure or dilution would push valuations lower. Traders should balance speculative upside against severe liquidity and fundamental risks. For more detail, see the company site and exchange listing, and use position sizing to manage intraday volatility. Meyka AI provides this as AI-powered market analysis for informed decision making.
FAQs
What is the current price and volume for ALDEI.PA stock?
ALDEI.PA stock trades intraday near €0.03 with volume at 13,014,939 shares on EURONEXT. Average volume is roughly 5,992,347, so today’s activity is about 2.17 times normal, raising short-term volatility.
What does Meyka AI say about ALDEI.PA stock?
Meyka AI rates ALDEI.PA 61.07/100, Grade B, Suggestion HOLD. The score mixes benchmark, sector and company metrics. The model projects €0.05 in 12 months, but forecasts are projections, not guarantees.
What are the main risks for ALDEI.PA stock traders?
Main risks for ALDEI.PA stock include limited liquidity, large intraday swings, negative EPS (-0.24), potential dilution and clinical trial setbacks. These factors make position sizing and stop rules essential for intraday trades.
Is there a published analyst price target for ALDEI.PA stock?
There is no broad analyst consensus or published price target for ALDEI.PA stock. Coverage is thin; Meyka AI supplies a model projection of €0.05, while conservative and optimistic bands should guide risk-adjusted positions.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
